Steve is a Partner at Digitalis. He currently represents Digitalis as a Director of Kenzen.
Steve is Chairman of the Board of Chromadex Corp. (Nasdaq: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food, beverage and cosmetic companies.
Drew is a Partner at Digitalis. He currently represents Digitalis as a Director of Somatix.
Previously Drew was the Head of New Ventures at Taylor Farms, the world’s largest processor of fresh-cut fruits and vegetables. During this time he led the creation and investment activity of Taylor Ventures, which invests in early-stage food and ag technology companies.
Carlos Bustamante is a population geneticist whose research focuses on analyzing genome wide patterns of variation within and between species to address fundamental questions in biology, anthropology, and medicine.
Dr. Brian Naughton was Founding Scientist and Vice President at 23andMe from its inception in 2006 until 2014. In this role, Naughton drew on his experience in bioinformatics, statistics and genetics to analyze data, develop algorithms and translate scientific research to drive the world's first Personal Genome Service.
Dr. Nedwin has over 30 years of experience in the pharmaceutical and industrial biotechnology industries. He is an accomplished senior executive with domestic and international experience in new market identification, innovation, research & development, business planning, strategic positioning, operations, P&L, sales & marketing, involving both start-up, growth and billion dollar organizations.